| First Author | Faramia J | Year | 2021 |
| Journal | Cell Rep Med | Volume | 2 |
| Issue | 4 | Pages | 100248 |
| PubMed ID | 33948578 | Mgi Jnum | J:349382 |
| Mgi Id | MGI:6728408 | Doi | 10.1016/j.xcrm.2021.100248 |
| Citation | Faramia J, et al. (2021) IGFBP-2 partly mediates the early metabolic improvements caused by bariatric surgery. Cell Rep Med 2(4):100248 |
| abstractText | Insulin-like growth factor-binding protein (IGFBP)-2 is a circulating biomarker of cardiometabolic health. Here, we report that circulating IGFBP-2 concentrations robustly increase after different bariatric procedures in humans, reaching higher levels after biliopancreatic diversion with duodenal switch (BPD-DS) than after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). This increase is closely associated with insulin sensitization. In mice and rats, BPD-DS and RYGB operations also increase circulating IGFBP-2 levels, which are not affected by SG or caloric restriction. In mice, Igfbp2 deficiency significantly impairs surgery-induced loss in adiposity and early improvement in insulin sensitivity but does not affect long-term enhancement in glucose homeostasis. This study demonstrates that the modulation of circulating IGFBP-2 may play a role in the early improvement of insulin sensitivity and loss of adiposity brought about by bariatric surgery. |
